MX2015012156A - Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. - Google Patents

Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.

Info

Publication number
MX2015012156A
MX2015012156A MX2015012156A MX2015012156A MX2015012156A MX 2015012156 A MX2015012156 A MX 2015012156A MX 2015012156 A MX2015012156 A MX 2015012156A MX 2015012156 A MX2015012156 A MX 2015012156A MX 2015012156 A MX2015012156 A MX 2015012156A
Authority
MX
Mexico
Prior art keywords
therapy
glatiramer acetate
followed
subject
rituximab
Prior art date
Application number
MX2015012156A
Other languages
English (en)
Inventor
Vollmer Timothy
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51527961&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2015012156(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of MX2015012156A publication Critical patent/MX2015012156A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/05—Containers specially adapted for medical or pharmaceutical purposes for collecting, storing or administering blood, plasma or medical fluids ; Infusion or perfusion containers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)

Abstract

La presente invención proporciona un método de tratamiento de un sujeto aquejado de una forma de esclerosis múltiple o que presenta un síndrome clínicamente aislado que comprende la administración periódica de una cantidad del anticuerpo anti-CD20 al menos dos veces al sujeto seguido de la administración periódica de una cantidad de acetato de glatiramer al sujeto, en donde las cantidades son eficaces para tratar al sujeto.
MX2015012156A 2013-03-12 2014-03-12 Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer. MX2015012156A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361778016P 2013-03-12 2013-03-12
PCT/US2014/025075 WO2014165280A1 (en) 2013-03-12 2014-03-12 Rituximab induction therapy followed by glatiramer acetate therapy

Publications (1)

Publication Number Publication Date
MX2015012156A true MX2015012156A (es) 2015-11-30

Family

ID=51527961

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015012156A MX2015012156A (es) 2013-03-12 2014-03-12 Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.

Country Status (18)

Country Link
US (3) US20140271630A1 (es)
EP (1) EP2968559A4 (es)
JP (1) JP2016512552A (es)
KR (1) KR20150138240A (es)
CN (1) CN105188751A (es)
AR (1) AR095372A1 (es)
AU (1) AU2014248524A1 (es)
BR (1) BR112015022538A2 (es)
CA (1) CA2903127A1 (es)
CL (1) CL2015002597A1 (es)
EA (1) EA201591687A1 (es)
HK (2) HK1218253A1 (es)
IL (1) IL240355A0 (es)
MX (1) MX2015012156A (es)
PE (1) PE20151937A1 (es)
TW (1) TW201521757A (es)
WO (1) WO2014165280A1 (es)
ZA (1) ZA201507489B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2405749B1 (en) 2009-08-20 2013-05-08 Yeda Research and Development Co., Ltd. Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
NZ609938A (en) 2010-10-11 2015-11-27 Teva Pharma Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
TW201326399A (zh) 2011-10-10 2013-07-01 Teva Pharma 用於預測對格拉替雷（ｇｌａｔｉｒａｍｅｒ）醋酸鹽之臨床反應之單核苷酸多型性之判定
US9617596B2 (en) 2012-10-10 2017-04-11 Teva Pharmaceutical Industries, Ltd. Biomarkers predictive for clinical response for glatiramer acetate
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9744920B2 (en) * 2015-04-21 2017-08-29 Mazda Motor Corporation Noise insulation structure of cabin floor
EP3600553A4 (en) 2017-03-26 2020-09-02 Mapi Pharma Ltd. GLATIRAMER DEPOT SYSTEMS FOR TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS
RU2020118519A (ru) * 2017-12-05 2022-01-10 Мабион Са Комбинированная терапия рассеянного склероза, включающая лиганд CD20
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) * 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR049200A1 (es) * 2004-06-04 2006-07-05 Genentech Inc Metodo para tratar esclerosis multiple con una composicion que contiene un anticuerpo cd20
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
AR078161A1 (es) * 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
US20130035390A1 (en) * 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
EP2667888A4 (en) * 2011-01-28 2015-11-11 Univ Oregon Health & Science LIGMPHES OF RECOMBINANT T LYMPHOCYTES AND ANTIBODIES BINDING TO LYMPHOCYTES B FOR THE TREATMENT OF AUTOIMMUNE DISEASES

Also Published As

Publication number Publication date
TW201521757A (zh) 2015-06-16
EP2968559A4 (en) 2016-11-02
CN105188751A (zh) 2015-12-23
AU2014248524A1 (en) 2015-10-29
HK1218253A1 (zh) 2017-02-10
WO2014165280A1 (en) 2014-10-09
BR112015022538A2 (pt) 2017-07-18
US20140271630A1 (en) 2014-09-18
KR20150138240A (ko) 2015-12-09
EA201591687A1 (ru) 2016-07-29
PE20151937A1 (es) 2016-01-15
HK1219413A1 (zh) 2017-04-07
US20160022811A1 (en) 2016-01-28
CL2015002597A1 (es) 2016-04-15
ZA201507489B (en) 2017-01-25
CA2903127A1 (en) 2014-10-09
JP2016512552A (ja) 2016-04-28
EP2968559A1 (en) 2016-01-20
AR095372A1 (es) 2015-10-14
IL240355A0 (en) 2015-09-24
US20170143824A1 (en) 2017-05-25

Similar Documents

Publication Publication Date Title
MX2015012156A (es) Terapia de induccion de rituximab seguida por terapia de acetato de glatiramer.
CA2909335C (en) Fenfluramine for use in the treatment of dravet syndrome
PH12015502075A1 (en) Treatment of cataplexy
MX2020011783A (es) Terapia de combinacion que involucra anticuerpos contra claudina 18.2 para tratamiento de cancer.
MX2016002645A (es) Tratamiento combinado para tratar el glioblastoma.
DK3791896T3 (da) Kombinationsterapi med antistoffer mod claudin 18.2 til cancerbehandling
BR112017003571A2 (pt) terapia combinada
BR112015026292A2 (pt) tratamento de câncer com dihidropirazino-pirazinas
WO2018039475A8 (en) Use of pridopidine for treating dystonias
MX2019003069A (es) Uso de pridopidina para tratar el sindrome de rett.
MX2015012444A (es) Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos.
MX2015010296A (es) Tratamiento de formas progresivas de esclerosis multiple con laquinimod.
MY198753A (en) Treatment of androgen deprivation therapy associated symptoms
MX2016001177A (es) Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
WO2014153505A3 (en) Treatment of chemotherapy-induced peripheral neuropathy
MX2016001179A (es) Tratamiento de esclerosis multiple por induccion de alemtuzumab seguido por terapia de laquinimod.
MX2016003763A (es) Terapia de combinacion con laquinimod para tratamiento de esclerosis multiple.
UA104614U (uk) Спосіб лікування хронічного токсокарозу в поєднанні з ентеробіозом у дорослих
MX2016008214A (es) Tratamiento de esclerosis multiple con una combinacion de laquinimod y teriflunomida.
UA103888U (uk) Розчин фенолу для ін'єкцій для лікування хронічного больового синдрому
NZ629683A (en) Methods for treating conditions associated with masp-2 dependent complement activation
UA84715U (ru) Способ лечения сахарного диабета типа 2 с ожирением